Immunomodulation by imiquimod in patients with high-risk primary melanoma

Imiquimod is a synthetic Toll-like receptor 7 (TLR7) agonist approved for the topical treatment of actinic keratoses, superficial basal cell carcinoma, and genital warts. Imiquimod leads to an 80–100% cure rate of lentigo maligna, but studies of invasive melanoma are lacking. We conducted a pilot st...

Descripción completa

Detalles Bibliográficos
Autores principales: Narayan, Rupa, Nguyen, Hong, Bentow, Jason J., Moy, Lauren, Lee, Diana K., Greger, Stephanie, Haskell, Jacquelyn, Vanchinathan, Veena, Chang, Pei-Lin, Tsui, Shanli, Konishi, Tamiko, Comin-Anduix, Begonya, Dauphine, Christine, Vargas, Hernan I., Economou, James S., Ribas, Antoni, Bruhn, Kevin W., Craft, Noah
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2011
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3229834/
https://www.ncbi.nlm.nih.gov/pubmed/21850019
http://dx.doi.org/10.1038/jid.2011.247

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3229834/
https://www.ncbi.nlm.nih.gov/pubmed/21850019
http://dx.doi.org/10.1038/jid.2011.247

Ejemplares similares